[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649741":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":40,"responsibleParty":62,"collaborators":18,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":18,"enrollmentInfo":75,"targetDuration":18,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":88,"whyStopped":18,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ambulatory ECG monitoring","EXPERIMENTAL","Participants will undergo ambulatory ECG monitoring at hospital discharge following TAVI. Continuous ECG monitoring will be performed for 14 days using an ambulatory ECG monitoring device. Clinically significant bradyarrhythmias or tachyarrhythmias detected during monitoring will be reviewed and managed according to clinical practice, including appropriate therapeutic interventions when indicated.",[13],"Device: Ambulatory ECG monitoring",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard care (no ambulatory ECG monitoring device).","NO_INTERVENTION","Participants will receive standard post-TAVI care without systematic ambulatory ECG monitoring at hospital discharge. Clinical follow-up will be performed according to routine practice.",null,[20],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":18},"DEVICE","Participants randomized to the intervention arm will undergo systematic ambulatory ECG monitoring at hospital discharge following the TAVI procedure. A wearable ambulatory ECG monitoring device will be applied for continuous rhythm monitoring during a 14-day period. The device will allow detection of clinically significant bradyarrhythmias and tachyarrhythmias. Detected arrhythmic events will be reviewed by the study team, and appropriate clinical management, including further evaluation or therapeutic intervention, will be performed according to the nature of the detected abnormality and standard clinical practice.",[9],[25],{"name":26,"affiliation":27,"role":28},"Josep Rodes-Cabau, MSc","Fondation IUCPQ","PRINCIPAL_INVESTIGATOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":18,"email":34},"Josep Rodes-Cabau, MD, PhD","CONTACT","14186568711","josep.rodes-cabau@criucpq.ulaval.ca",{"name":36,"role":32,"phone":37,"phoneExt":38,"email":39},"Emilie Pelletier Beaumont, MSc","4186568711","3929","emilie.pelletier-beaumont@criucpq.ulaval",[41],{"facility":42,"status":18,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Institut universitaire de cardiologie et de pneumologie de Québec - UL","Québec","Quebec","G1Y 4G5","Canada","CA",{"type":49,"coordinates":50},"Point",[51,52],-71.21454,46.81228,{"lat":52,"lon":51},[55,58,59],{"name":56,"role":32,"phone":37,"phoneExt":38,"email":57},"Emilie Pelletier beaumont, MSc","emilie.pelletier-beaumont@criucpq.ulaval.ca",{"name":31,"role":28,"phone":18,"phoneExt":18,"email":18},{"name":60,"role":61,"phone":18,"phoneExt":18,"email":18},"Francois Philippon, MD","SUB_INVESTIGATOR",{"type":28,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Josep Rodes-Cabau","Principal Investigator","100649741","systematic-ambulatory-ecg-monitoring-following-tavi-100649741",false,"NCT07739316","Systematic Ambulatory ECG Monitoring Following TAVI","Systematic Ambulatory ECG Monitoring Following TAVI: A Prospective Randomized Trial.","RECORDII","Inclusion Criteria:\n\n* Age \\>18 years\n* Successful TAVI procedure.\n* Hospitalization discharge ≤72 hrs following the TAVI procedure.\n* Presence of at least 1 ECG abnormality at hospital discharge (QRS ≥120 ms OR PR ≥200 ms)\n\nExclusion Criteria:\n\n* Pacemaker implantation (pre- TAVI or during hospitalization after the procedure).\n* TAVI valve-in-valve procedure\n* Any complication or logistic reason precluding hospital discharge ≤72 hrs following the TAVI procedure.\n* Impossibility to obtain signed informed consent.","ALL","18 Years",{"count":76,"type":77},754,"ESTIMATED","INTERVENTIONAL",[80],"NA","This multicenter, prospective, randomized superiority trial will evaluate whether systematic 14-day ambulatory ECG monitoring following hospital discharge after transcatheter aortic valve implantation (TAVI) reduces the risk of sudden death, symptomatic arrhythmic events, or stroke within 1 year compared with standard post-discharge care. Patients undergoing successful TAVI without permanent pacemaker implantation and presenting with at least one ECG conduction abnormality at hospital discharge will be randomized to receive either ambulatory ECG monitoring or standard follow-up. All participants will undergo routine clinical follow-up at 30 days and 1 year after TAVI.",[83,84],"Aortic Stenosis","Conduction Disturbances",[86,87],"TAVI","Ambulatory Electrocardiographic Monitoring","NOT_YET_RECRUITING","2026-07-27",{"date":91,"type":92},"2026-07-31","ACTUAL",{"date":94,"type":77},"2026-08",{"date":96,"type":77},"2028-12",{"name":5,"class":6},1]